• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Allarity Therapeutics, Inc. - Common stock (NQ:ALLR)

    1.040 +0.045 (+4.52%)
    Streaming Delayed Price Updated: 4:00 PM EST, Mar 3, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 217,271
    Open 0.9900
    Bid (Size) 1.080 (100)
    Ask (Size) 1.150 (100)
    Prev. Close 0.9950
    Today's Range 0.9501 - 1.120
    52wk Range 0.6138 - 2.350
    Shares Outstanding 365,173,471
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need
    From Allarity Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran’s Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment
    From Allarity Therapeutics, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -8.8%
    -8.8%
    1 Month
    +7.9%
    +7.9%
    3 Month
    -13.3%
    -13.3%
    6 Month
    -35.0%
    -35.0%
    1 Year
    +18.2%
    +18.2%

    More News

    Read More
    News headline image
    Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders
    From Allarity Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates
    From Allarity Therapeutics, Inc.
    Via GlobeNewswire
    Why Did Allarity Therapeutics Stock Double In Value Today? ↗
    Via Stocktwits
    News headline image
    12 Health Care Stocks Moving In Monday's Intraday Session ↗
    Via Benzinga
    News headline image
    Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months
    From Allarity Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Allarity Therapeutics CEO to Present at Biomarkers & Precision Medicine 2025
    From Allarity Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    These stocks have an unusual volume in today's session ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Top stock movements in today's session. ↗
    Via Chartmill
    News headline image
    Check out the stocks that are attracting the most attention and driving market activity. ↗
    Via Chartmill
    News headline image
    Power Metallic’s (TSX-V: PNPN | OTCQB: PNPNF) Strategic Appointment Signals Major Paradigm Shift Ahead – More Stocks Inside
    Via AB Newswire
    Topics Government
    News headline image
    12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
    Via Benzinga
    News headline image
    Tuesday's session: top gainers and losers ↗
    Via Chartmill
    News headline image
    Crude Oil Down 2%; US Durable Goods Orders Decline In July ↗
    Via Benzinga
    News headline image
    Traders are paying attention to the gapping stocks in Tuesday's session. ↗
    Via Chartmill
    News headline image
    US Stocks Mixed; American Woodmark Posts Downbeat Sales ↗
    Via Benzinga
    News headline image
    Tuesday's pre-market session: top gainers and losers ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Allarity Therapeutics Granted FDA Fast Track Designation for Stenoparib for the Treatment of Advanced Ovarian Cancer
    From Allarity Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Stock Market Today: S&P 500, Nasdaq Futures Decline— Palo Alto, XP, Allarity Earnings In Focus ↗
    Via Benzinga
    Topics Stocks
    News headline image
    Palo Alto Networks, Fabrinet And 3 Stocks To Watch Heading Into Monday ↗
    Via Benzinga
    News headline image
    Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships
    From Allarity Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    This MongoDB Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
    Via Benzinga

    Frequently Asked Questions

    Is Allarity Therapeutics, Inc. - Common stock publicly traded?
    Yes, Allarity Therapeutics, Inc. - Common stock is publicly traded.
    What exchange does Allarity Therapeutics, Inc. - Common stock trade on?
    Allarity Therapeutics, Inc. - Common stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Allarity Therapeutics, Inc. - Common stock?
    The ticker symbol for Allarity Therapeutics, Inc. - Common stock is ALLR on the Nasdaq Stock Market
    What is the current price of Allarity Therapeutics, Inc. - Common stock?
    The current price of Allarity Therapeutics, Inc. - Common stock is 1.040
    When was Allarity Therapeutics, Inc. - Common stock last traded?
    The last trade of Allarity Therapeutics, Inc. - Common stock was at 03/03/26 04:00 PM ET
    What is the market capitalization of Allarity Therapeutics, Inc. - Common stock?
    The market capitalization of Allarity Therapeutics, Inc. - Common stock is 379.78M
    How many shares of Allarity Therapeutics, Inc. - Common stock are outstanding?
    Allarity Therapeutics, Inc. - Common stock has 380M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.